Latest news with #Benzinga.com
Yahoo
11 hours ago
- Business
- Yahoo
Can You Guess What The Rich Are Investing In? Nearly a Quarter of Their Wealth Is Tied To One Asset — And It's Not Stocks
Is the typical rich person's portfolio packed with tech stocks, startup equity, and private hedge funds? Maybe a pile of municipal bonds, mutual funds, or just an eye-watering amount of cash sitting idle? Depends who you ask. While the headlines scream about AI stocks and crypto millionaires, the wealthiest individuals on the planet are quietly putting their money somewhere much more stable — and far less flashy. According to Knight Frank's Wealth Report 2025, wealthy investors are still betting big on real estate. In fact, 22.5% of their portfolios are made up of direct property investments — nearly a quarter of their wealth, parked in something tangible. Don't Miss: Hasbro, MGM, and Skechers trust this AI marketing firm — And that share is expected to grow. The report found that 44% of wealthy individuals plan to increase how much they invest in real estate over the next 18 months. It's not about flipping houses — it's about buying long-term, cash-generating, inflation-resistant assets. The top choices aren't just beachfront estates, though those still make the cut. The biggest growth areas include: Luxury homes in high-demand cities Dubai, Lisbon, and Miami Industrial and logistics properties, which are booming thanks to e-commerce Housing sectors like student apartments and senior living, where demand keeps climbing This isn't a short-term play. Wealthy investors are holding these properties for nine years or more, according to the report — focusing on long-term income and stability, not market timing. Trending: Maximize saving for your retirement and cut down on taxes: . Real estate offers something stocks, crypto, and startup equity don't: control and consistency. The wealthy use property to preserve wealth, generate steady rental income, and pass on long-term value to future generations. And when markets get rocky, real estate gives them something solid to lean on — literally. While everyday investors chase trends and try to time the next breakout stock, the rich are loading up on what they know works. Real estate isn't just a line on a portfolio — it's the bedrock. Whether it's a rental property in Portugal or a warehouse in Austin, Texas, it's the asset they trust to do the heavy lifting. And if nearly a quarter of their wealth is already there — with plans to pour in more — maybe it's time to ask: what do they know that the average investor doesn't? Read Next: Here's what Americans think you need to be considered Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? APPLE (AAPL): Free Stock Analysis Report TESLA (TSLA): Free Stock Analysis Report This article Can You Guess What The Rich Are Investing In? Nearly a Quarter of Their Wealth Is Tied To One Asset — And It's Not Stocks originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
2 days ago
- Business
- Yahoo
Pfizer Reports Survival Gains In Colorectal Cancer Study, Combo Therapy Cuts Death Risk By Over 50%
Pfizer Inc. (NYSE:PFE) on Friday released data from Phase 3 BREAKWATER trial evaluating BRAFTOVI (encorafenib) in combination with cetuximab (marketed as ERBITUX) and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) for metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. The study showed statistically significant and clinically meaningful survival results. The data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and published in the New England Journal of a second interim analysis of overall survival (OS), a key secondary endpoint, the BRAFTOVI combination regimen reduced the risk of death by 51% compared to standard-of-care chemotherapy with or without bevacizumab (Hazard Ratio [HR] 0.49). Median OS was 30.3 months with BRAFTOVI in combination with cetuximab and mFOLFOX6 compared to 15.1 months with chemotherapy with or without bevacizumab. In the primary analysis of progression-free survival (PFS), the BRAFTOVI combination regimen reduced the risk of disease progression or death by 47% compared to standard-of-care chemotherapy with or without bevacizumab (HR 0.53) as assessed by blinded independent central review (BICR). Median PFS was 12.8 months with the BRAFTOVI combination regimen compared to 7.1 months. The updated objective response rate (ORR) by BICR confirmed the improvement previously observed with the BRAFTOVI combination regimen compared to patients receiving chemotherapy with or without bevacizumab. The prior primary analysis also maintained the estimated median duration of response and median time to response. The BRAFTOVI combination regimen received accelerated approval by the U.S. Food and Drug Administration (FDA) in December 2024 for patients with BRAF V600E -mutant mCRC based on a clinically meaningful and statistically significant improvement in confirmed ORR in treatment-naïve patients, the study's other dual primary endpoint. Continued approval for this indication is contingent upon verification of clinical benefit. The BREAKWATER survival data are being discussed with the U.S. FDA to support potential conversion to full approval in 2025. Price Action: PFE stock is up 0.51% at $23.57 at the last check on Friday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? PFIZER (PFE): Free Stock Analysis Report This article Pfizer Reports Survival Gains In Colorectal Cancer Study, Combo Therapy Cuts Death Risk By Over 50% originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. 登入存取你的投資組合
Yahoo
3 days ago
- Business
- Yahoo
Roche's Multiple Sclerosis Drug Shows Low Disease Activity Over Two Years
Roche Holdings AG (OTC:RHHBY) on Friday announced new 96-week data for fenebrutinib demonstrating that patients with relapsing multiple sclerosis (RMS) maintained no disability progression and low disease activity levels for up to two years. The latest results for this investigational Bruton's tyrosine kinase (BTK) inhibitor from the Phase II FENopta open-label extension (OLE) study were presented at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting. Ninety-nine patients entered the OLE and 93 remained in the OLE after 96 the OLE period, patients treated with fenebrutinib for up to 96 weeks had a low annualised relapse rate (ARR) of 0.06, and during this time there was no disability progression, as measured by the Expanded Disability Status Scale (EDSS). MRI scans showed that fenebrutinib treatment suppressed disease activity in the brain. At 96 weeks zero new T1 gadolinium-enhancing (T1-Gd+) lesions, which are markers of active inflammation, were detected. In the treatment group that switched from placebo to fenebrutinib in the OLE, the annualized rate of new or enlarging T2 lesions, which represent chronic disease burden, decreased from 6.72 at the end of the 12-week double-blind period to 0.34 by 96 weeks. The safety profile of fenebrutinib in the OLE was consistent with previously reported data, with no new safety concerns identified at 96 weeks. During the OLE, one patient experienced asymptomatic alanine aminotransferase elevation at OLE week 4, after 16 weeks on treatment, which resolved with treatment discontinuation. Three Phase 3 trials are ongoing, including the FENhance 1 and 2 trials in RMS and the FENtrepid trial in primary progressive multiple sclerosis (PPMS). The first data from these studies are expected at the end of 2025. In April, Roche announced it would invest $50 billion in the U.S. over the next five years. These investments further strengthen Roche's already significant U.S. footprint, which includes 13 manufacturing and 15 R&D sites across the Pharmaceutical and Diagnostics Divisions. The investment is expected to create over 12,000 new jobs, including nearly 6,500 construction jobs and 1,000 jobs at new and expanded facilities. Price Action: RHHBY stock is trading higher by 1.83% to $40.25 at last check Friday. Read Next:Photo by OleksSH via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Roche's Multiple Sclerosis Drug Shows Low Disease Activity Over Two Years originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%
Keros Therapeutics Inc (NASDAQ:KROS) released topline data from the TROPOS Phase 2 trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension (PAH) on Wednesday. In December 2024, the company voluntarily halted the 3.0 mg/kg and 4.5 mg/kg treatment arms based on observing pericardial effusions at those dose levels. Furthermore, in January 2025, the company halted all dosing in the trial, including the 1.5 mg/kg and placebo treatment arms, based on the ongoing safety review due to new observations of pericardial effusion adverse the early termination of the trial, patients continued to be monitored through their end-of-trial visits. Following the analysis of all available safety and efficacy data from the TROPOS trial, the company has decided to discontinue all development of cibotercept in PAH. In a corporate presentation, the company noted a higher incidence in cibotercept arms relative to placebo and a higher incidence rate and severity in the 3.0 and 4.5 mg/kg arms than the 1.5 mg/kg arm. The background rate of pericardial effusions in this trial was higher than in randomized, controlled trials of Merck & Company, Inc.'s (NYSE:MRK) Winrevair (sotatercept). Keros said the ability to interpret 24-week data is limited due to incomplete treatment duration and trial visit participation. A dose-dependent signal for pericardial effusions was observed for cibotercept in this PAH population. During the treatment duration in the analysis from this data cutoff, no major signal for hemoglobin increases, thrombocytopenia, bleeding events, or telangiectasias was observed relative to the placebo. No clinically meaningful improvement in pulmonary vascular resistance (PVR) or 6-minute walk distance (6MWD) was observed. The company plans to further evaluate the appropriate development strategy for cibotercept, if any, in other indications following the completion of the strategic alternative review process. Keros has decided to reduce the company's headcount by approximately 45%, after which the company will have 85 full-time employees. The company expects to realize average annualized cost savings of approximately $17 million. Price Action: KROS stock is trading lower by 4.78% to $13.94 at last check Thursday. Read Next:Image via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45% originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Business
- Yahoo
Chinese Stocks Soar As US Court Blocks Trump Tariffs
U.S.-listed Chinese stocks led by Alibaba Group Holding (NYSE:BABA), PDD Holdings Inc (NASDAQ:PDD), and Baidu, Inc (NASDAQ:BIDU) gained on Thursday after a federal court invalidated global tariffs enacted by President Donald Trump under the International Emergency Economic Powers Act on Wednesday. A three-judge panel, with appointees from the Reagan, Obama and Trump eras, ruled that the IEEPA doesn't give the president unlimited power to impose tariffs. Reportedly, the Trump administration filed an appeal against the ruling in Chinese electric vehicle companies, including NIO Inc (NYSE: NIO) and XPeng Inc (NYSE: XPEV), also noted strong upward momentum. On May 12, Beijing and Washington agreed to lower tariffs on each other's products, temporarily offering relief to the stock market. The deal reduced U.S. levies of 145% on most Chinese imports to 30%, while China's 125% duties on U.S. goods will drop to 10% for 90 days. In April, President Trump hinted at a significant reduction in tariff rates. During an investor summit, Treasury Secretary Scott Bessent acknowledged the impracticability and mutual challenges of a tariff war with China. U.S. chip designer Nvidia Corp (NASDAQ:NVDA) reported first-quarter results on Wednesday. It faced an export ban on H20 products to China on April 9. The company said it incurred a $4.5 billion charge in the first quarter related to H20 excess inventory and purchase obligations. Price Actions: BABA stock is up 0.50%, and PDD is up 1.20% at the last check Thursday. Read Next:Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? APPLE (AAPL): Free Stock Analysis Report TESLA (TSLA): Free Stock Analysis Report This article Chinese Stocks Soar As US Court Blocks Trump Tariffs originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
